Centogene NV
NASDAQ:CNTG
Intrinsic Value
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical c... [ Read More ]
The intrinsic value of one CNTG stock under the Base Case scenario is 6.7 USD. Compared to the current market price of 0.71 USD, Centogene NV is Undervalued by 89%.
Valuation Backtest
Centogene NV
Run backtest to discover the historical profit from buying and selling CNTG stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Centogene NV
Current Assets | 38.9m |
Cash & Short-Term Investments | 14.2m |
Receivables | 17.9m |
Other Current Assets | 6.8m |
Non-Current Assets | 33m |
Long-Term Investments | 300k |
PP&E | 21.6m |
Intangibles | 8.2m |
Other Non-Current Assets | 2.9m |
Current Liabilities | 26.9m |
Accounts Payable | 7m |
Other Current Liabilities | 19.9m |
Non-Current Liabilities | 60.2m |
Long-Term Debt | 53.1m |
Other Non-Current Liabilities | 7.1m |
Earnings Waterfall
Centogene NV
Revenue
|
72.1m
EUR
|
Cost of Revenue
|
-42.8m
EUR
|
Gross Profit
|
29.3m
EUR
|
Operating Expenses
|
-86.2m
EUR
|
Operating Income
|
-56.9m
EUR
|
Other Expenses
|
579k
EUR
|
Net Income
|
-56.3m
EUR
|
Free Cash Flow Analysis
Centogene NV
What is Free Cash Flow?
CNTG Profitability Score
Profitability Due Diligence
Centogene NV's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Centogene NV's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
CNTG Solvency Score
Solvency Due Diligence
Centogene NV's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
Centogene NV's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CNTG Price Targets Summary
Centogene NV
According to Wall Street analysts, the average 1-year price target for CNTG is 1.53 USD with a low forecast of 1.52 USD and a high forecast of 1.58 USD.
Shareholder Return
CNTG Price
Centogene NV
Average Annual Return | -36.2% |
Standard Deviation of Annual Returns | 39.12% |
Max Drawdown | -97% |
Market Capitalization | 19.8m USD |
Shares Outstanding | 27 865 800 |
Percentage of Shares Shorted | 0.22% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 808 full-time employees. The company went IPO on 2019-11-07. The company focuses on transforming clinical, genetic and biochemical data into medical solutions for patients, physicians and pharmaceutical companies. The firm provides the full spectrum of methods and technology for human genetics analysis. The company develops a rare disease platform based on its real-world data repository with over 2.0 billion weighted data points from over 450,000 patients representing around 115 different, which includes epidemiologic, phenotypic and genetic data that reflects a global population, as well as a biobank of patients’ blood samples. In addition, it is active in the research and development products for human genetics. The firm operates in Germany and the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one CNTG stock under the Base Case scenario is 6.7 USD.
Compared to the current market price of 0.71 USD, Centogene NV is Undervalued by 89%.